Deals
FCC Clears AT&T, Starlink EchoStar Spectrum Deals
The FCC cleared EchoStar spectrum for AT&T and Starlink, leaving rural carriers to fight for secondary deals that may never materialize.
Deals — Page 4
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Isomorphic Closes $2.1B Series B, Second Biggest Biotech
Alphabet's Isomorphic Labs closed a $2.1B Series B, the second biggest biotech fundraise ever, with no pipeline molecule disclosed.
Deals
BMS Buys Into Hengrui 13-Asset Pipeline for $950M
BMS commits $950M up front for a 13-asset onco-immune pipeline with Hengrui that could balloon to $15.2B if every milestone clears.
Deals
Booked $5B Write-Down, CSL Hits Nine-Year Low
CSL's $5B write-down paired with a 4% guidance cut drove shares to a nine-year low; investors aren't convinced the cleanup is done.
Deals
Odyssey Prices $304M IPO at $18, Bets on RIPK2
Odyssey Therapeutics priced a $304M IPO at $18 per share, at the top of its range, with $135M earmarked for a RIPK2 inhibitor in ulcerative colitis.
Deals
Lilly Drops $4.5B, Opens First Genetic Medicine Plant
Lilly's $4.5B Indiana bet includes the company's first genetic medicine plant and what could become the largest API site in U.S. history.
Deals
Roche Buys PathAI for $750M, Up to $1.05B Total
Roche is dropping $750M upfront for PathAI, with another $300M in milestones riding on a pathology software platform it wants to take global.
Deals
Angelini Pays $4.1B for Catalyst's Rare Neuro Drugs
Angelini Pharma dropped $4.1B on Catalyst and its trio of FDA-approved rare neurology treatments; the per-share premium wasn't disclosed.
Deals
GSK Bought SiranBio for $1B in siRNA Bet
GSK paid up to $1B for SiranBio's Phase 1 siRNA asset targeting ALK7, doubling down on cardiometabolic bets while GLP-1 rivals pile up.
Deals
Lilly Puts $4.5B More Into Indiana Complex
Lilly's $4.5B Lebanon push brings its U.S. decade commitment over $50B, with a tirzepatide API plant poised to be the country's largest.
Deals
Bullish Buys Transfer Agent Equiniti for $4.2B
The crypto exchange is paying $4.2B for capital markets plumbing: a transfer agent processing $500B annually for 20 million shareholders.
Deals
Madrigal Pays $25M Up, Bets $1B on Arrowhead RNAi
Madrigal's $1B bet on Arrowhead's ARO-PNPLA3 targets a PNPLA3 mutation affecting 30% of MASH patients that Rezdiffra doesn't cover.
Deals
Amgen Adds $300M to Puerto Rico Biologics Site
Amgen drops another $300M into its Puerto Rico biologics site, bringing Juncos to nearly $1B total and U.S. manufacturing pledges close to $2B.
Deals
Bid $55.5B for eBay: GameStop Can't Cover It
GameStop offered $55.5B for eBay at $125 a share, a 46% premium, but CNBC's math found a $16 billion gap Ryan Cohen couldn't explain.
Deals
Windward Bio Raises $165M for Late-Stage Trial
Swiss biotech Windward Bio raised $165M to advance a China-derived drug into late-stage testing. What investors get from this bet is the real question.
Deals
Ken Song's T Cell Engager Bet Gets Picked Up
Ken Song has done it again.
Deals
Bought Candid for $2B, UCB Challenges Gilead on TCE
UCB bought Candid Therapeutics for $2 billion upfront, plus up to $200 million in development milestones, cutting off a planned reverse merger with…
Deals
Novartis Seals $23B US Build With NC API Plant
Novartis has committed $23 billion to build seven U.S. facilities, and the final piece just landed in Morrisville, North Carolina: a 56,200-square-foot…
Deals
Bought: Sun Pharma's $11.75B Organon Deal
Sun Pharma paid $11.75 billion for Organon, the largest biopharma acquisition of 2026 and the biggest deal any Indian drugmaker has ever announced.
Deals
BeOne Buys $2B Option on Huahui Trispecific
BeOne Medicines is paying $20 million upfront to reserve an exclusive option on HH160, a preclinical trispecific antibody from Beijing-based Huahui Health.
